Although gefitinib has been approved by the Food and Drug Administration (FDA) of USA as a first-line drug for the treatment of EGFR-activated mutants NSCLC [12], acquired resistance and recurrence are inevitable in most patients 9–13 months after treatment, and genetic testing indicated that the T790M mutation in exon 20 is the main cause of drug resistance [13]. Here, EGFR is linked to non-small cell lung carcinoma.